nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—PTGS2—thyroid cancer	0.761	1	CbGaD
Nabumetone—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00516	0.133	CbGpPWpGaD
Nabumetone—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00409	0.106	CbGpPWpGaD
Nabumetone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00388	0.1	CbGpPWpGaD
Nabumetone—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00308	0.0794	CbGpPWpGaD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00211	0.0544	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00183	0.0473	CbGpPWpGaD
Nabumetone—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00167	0.0432	CbGpPWpGaD
Nabumetone—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.0014	0.0361	CbGpPWpGaD
Nabumetone—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00111	0.0287	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00109	0.028	CbGpPWpGaD
Nabumetone—Myocardial infarction—Sorafenib—thyroid cancer	0.00102	0.00512	CcSEcCtD
Nabumetone—Jaundice—Sorafenib—thyroid cancer	0.00102	0.00509	CcSEcCtD
Nabumetone—Stomatitis—Sorafenib—thyroid cancer	0.00102	0.00509	CcSEcCtD
Nabumetone—Dry mouth—Vandetanib—thyroid cancer	0.00101	0.00504	CcSEcCtD
Nabumetone—Oedema—Vandetanib—thyroid cancer	0.000988	0.00494	CcSEcCtD
Nabumetone—Thrombocytopenia—Vandetanib—thyroid cancer	0.000967	0.00483	CcSEcCtD
Nabumetone—Haemoglobin—Sorafenib—thyroid cancer	0.000943	0.00471	CcSEcCtD
Nabumetone—Haemorrhage—Sorafenib—thyroid cancer	0.000938	0.00469	CcSEcCtD
Nabumetone—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.000933	0.00466	CcSEcCtD
Nabumetone—Albuminuria—Epirubicin—thyroid cancer	0.000925	0.00462	CcSEcCtD
Nabumetone—Insomnia—Vandetanib—thyroid cancer	0.000894	0.00446	CcSEcCtD
Nabumetone—Paraesthesia—Vandetanib—thyroid cancer	0.000887	0.00443	CcSEcCtD
Nabumetone—Erythema multiforme—Sorafenib—thyroid cancer	0.000887	0.00443	CcSEcCtD
Nabumetone—Dyspnoea—Vandetanib—thyroid cancer	0.000881	0.0044	CcSEcCtD
Nabumetone—Gingivitis—Epirubicin—thyroid cancer	0.00088	0.00439	CcSEcCtD
Nabumetone—Tinnitus—Sorafenib—thyroid cancer	0.000875	0.00437	CcSEcCtD
Nabumetone—Dyspepsia—Vandetanib—thyroid cancer	0.00087	0.00435	CcSEcCtD
Nabumetone—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.000863	0.00431	CcSEcCtD
Nabumetone—Decreased appetite—Vandetanib—thyroid cancer	0.000859	0.00429	CcSEcCtD
Nabumetone—Albuminuria—Doxorubicin—thyroid cancer	0.000856	0.00427	CcSEcCtD
Nabumetone—Fatigue—Vandetanib—thyroid cancer	0.000852	0.00426	CcSEcCtD
Nabumetone—Constipation—Vandetanib—thyroid cancer	0.000845	0.00422	CcSEcCtD
Nabumetone—Arrhythmia—Sorafenib—thyroid cancer	0.000838	0.00419	CcSEcCtD
Nabumetone—Alopecia—Sorafenib—thyroid cancer	0.000829	0.00414	CcSEcCtD
Nabumetone—Gingivitis—Doxorubicin—thyroid cancer	0.000814	0.00407	CcSEcCtD
Nabumetone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000808	0.00404	CcSEcCtD
Nabumetone—Jaundice cholestatic—Epirubicin—thyroid cancer	0.000786	0.00393	CcSEcCtD
Nabumetone—Body temperature increased—Vandetanib—thyroid cancer	0.000781	0.0039	CcSEcCtD
Nabumetone—Abdominal pain—Vandetanib—thyroid cancer	0.000781	0.0039	CcSEcCtD
Nabumetone—Rectal haemorrhage—Epirubicin—thyroid cancer	0.000764	0.00382	CcSEcCtD
Nabumetone—Anaemia—Sorafenib—thyroid cancer	0.000755	0.00377	CcSEcCtD
Nabumetone—Glossitis—Epirubicin—thyroid cancer	0.000749	0.00374	CcSEcCtD
Nabumetone—Angioedema—Sorafenib—thyroid cancer	0.000746	0.00373	CcSEcCtD
Nabumetone—Hyperuricaemia—Epirubicin—thyroid cancer	0.000744	0.00372	CcSEcCtD
Nabumetone—Syncope—Sorafenib—thyroid cancer	0.000732	0.00366	CcSEcCtD
Nabumetone—Leukopenia—Sorafenib—thyroid cancer	0.000731	0.00365	CcSEcCtD
Nabumetone—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.000727	0.00363	CcSEcCtD
Nabumetone—Loss of consciousness—Sorafenib—thyroid cancer	0.000718	0.00359	CcSEcCtD
Nabumetone—Cough—Sorafenib—thyroid cancer	0.000713	0.00356	CcSEcCtD
Nabumetone—Asthenia—Vandetanib—thyroid cancer	0.000709	0.00354	CcSEcCtD
Nabumetone—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.000707	0.00353	CcSEcCtD
Nabumetone—Hypertension—Sorafenib—thyroid cancer	0.000705	0.00352	CcSEcCtD
Nabumetone—Blood uric acid increased—Epirubicin—thyroid cancer	0.000703	0.00351	CcSEcCtD
Nabumetone—Pruritus—Vandetanib—thyroid cancer	0.000699	0.00349	CcSEcCtD
Nabumetone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.000696	0.018	CbGpPWpGaD
Nabumetone—Glossitis—Doxorubicin—thyroid cancer	0.000693	0.00346	CcSEcCtD
Nabumetone—Hyperuricaemia—Doxorubicin—thyroid cancer	0.000689	0.00344	CcSEcCtD
Nabumetone—Dry mouth—Sorafenib—thyroid cancer	0.00068	0.0034	CcSEcCtD
Nabumetone—Eructation—Epirubicin—thyroid cancer	0.000678	0.00339	CcSEcCtD
Nabumetone—Diarrhoea—Vandetanib—thyroid cancer	0.000676	0.00338	CcSEcCtD
Nabumetone—Melaena—Epirubicin—thyroid cancer	0.000674	0.00337	CcSEcCtD
Nabumetone—Anaphylactic shock—Sorafenib—thyroid cancer	0.000666	0.00333	CcSEcCtD
Nabumetone—Shock—Sorafenib—thyroid cancer	0.000656	0.00328	CcSEcCtD
Nabumetone—Dizziness—Vandetanib—thyroid cancer	0.000653	0.00326	CcSEcCtD
Nabumetone—Thrombocytopenia—Sorafenib—thyroid cancer	0.000652	0.00326	CcSEcCtD
Nabumetone—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00065	0.00325	CcSEcCtD
Nabumetone—Aplastic anaemia—Epirubicin—thyroid cancer	0.000648	0.00324	CcSEcCtD
Nabumetone—Anorexia—Sorafenib—thyroid cancer	0.000635	0.00317	CcSEcCtD
Nabumetone—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000629	0.0162	CbGpPWpGaD
Nabumetone—Vomiting—Vandetanib—thyroid cancer	0.000628	0.00314	CcSEcCtD
Nabumetone—Eructation—Doxorubicin—thyroid cancer	0.000628	0.00314	CcSEcCtD
Nabumetone—Melaena—Doxorubicin—thyroid cancer	0.000624	0.00312	CcSEcCtD
Nabumetone—Rash—Vandetanib—thyroid cancer	0.000623	0.00311	CcSEcCtD
Nabumetone—Dermatitis—Vandetanib—thyroid cancer	0.000622	0.00311	CcSEcCtD
Nabumetone—Headache—Vandetanib—thyroid cancer	0.000619	0.00309	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.000615	0.0159	CbGpPWpGaD
Nabumetone—Abnormal vision—Epirubicin—thyroid cancer	0.000602	0.00301	CcSEcCtD
Nabumetone—Aplastic anaemia—Doxorubicin—thyroid cancer	0.0006	0.003	CcSEcCtD
Nabumetone—Dyspnoea—Sorafenib—thyroid cancer	0.000594	0.00297	CcSEcCtD
Nabumetone—Nausea—Vandetanib—thyroid cancer	0.000587	0.00293	CcSEcCtD
Nabumetone—Dyspepsia—Sorafenib—thyroid cancer	0.000587	0.00293	CcSEcCtD
Nabumetone—Decreased appetite—Sorafenib—thyroid cancer	0.000579	0.00289	CcSEcCtD
Nabumetone—Thrombophlebitis—Epirubicin—thyroid cancer	0.000579	0.00289	CcSEcCtD
Nabumetone—Fatigue—Sorafenib—thyroid cancer	0.000575	0.00287	CcSEcCtD
Nabumetone—Photosensitivity—Epirubicin—thyroid cancer	0.000571	0.00285	CcSEcCtD
Nabumetone—Constipation—Sorafenib—thyroid cancer	0.00057	0.00285	CcSEcCtD
Nabumetone—Hepatic failure—Epirubicin—thyroid cancer	0.000558	0.00279	CcSEcCtD
Nabumetone—Abnormal vision—Doxorubicin—thyroid cancer	0.000557	0.00278	CcSEcCtD
Nabumetone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000545	0.00272	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000545	0.0141	CbGpPWpGaD
Nabumetone—Thrombophlebitis—Doxorubicin—thyroid cancer	0.000536	0.00268	CcSEcCtD
Nabumetone—Increased appetite—Epirubicin—thyroid cancer	0.000533	0.00266	CcSEcCtD
Nabumetone—Urticaria—Sorafenib—thyroid cancer	0.000529	0.00265	CcSEcCtD
Nabumetone—Photosensitivity—Doxorubicin—thyroid cancer	0.000528	0.00264	CcSEcCtD
Nabumetone—Abdominal pain—Sorafenib—thyroid cancer	0.000527	0.00263	CcSEcCtD
Nabumetone—Body temperature increased—Sorafenib—thyroid cancer	0.000527	0.00263	CcSEcCtD
Nabumetone—Dermatitis bullous—Epirubicin—thyroid cancer	0.000524	0.00262	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000518	0.00259	CcSEcCtD
Nabumetone—Hepatic failure—Doxorubicin—thyroid cancer	0.000516	0.00258	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000501	0.0025	CcSEcCtD
Nabumetone—Increased appetite—Doxorubicin—thyroid cancer	0.000493	0.00247	CcSEcCtD
Nabumetone—Hypersensitivity—Sorafenib—thyroid cancer	0.000491	0.00245	CcSEcCtD
Nabumetone—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000485	0.00242	CcSEcCtD
Nabumetone—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000479	0.00239	CcSEcCtD
Nabumetone—Asthenia—Sorafenib—thyroid cancer	0.000478	0.00239	CcSEcCtD
Nabumetone—Pruritus—Sorafenib—thyroid cancer	0.000471	0.00236	CcSEcCtD
Nabumetone—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000464	0.00232	CcSEcCtD
Nabumetone—Liver function test abnormal—Epirubicin—thyroid cancer	0.000463	0.00231	CcSEcCtD
Nabumetone—Hypokalaemia—Epirubicin—thyroid cancer	0.000456	0.00228	CcSEcCtD
Nabumetone—Diarrhoea—Sorafenib—thyroid cancer	0.000456	0.00228	CcSEcCtD
Nabumetone—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000452	0.0117	CbGpPWpGaD
Nabumetone—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000451	0.00225	CcSEcCtD
Nabumetone—Gastritis—Epirubicin—thyroid cancer	0.000443	0.00222	CcSEcCtD
Nabumetone—Dizziness—Sorafenib—thyroid cancer	0.000441	0.0022	CcSEcCtD
Nabumetone—Dysphagia—Epirubicin—thyroid cancer	0.000433	0.00216	CcSEcCtD
Nabumetone—Asthma—Epirubicin—thyroid cancer	0.000433	0.00216	CcSEcCtD
Nabumetone—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000428	0.00214	CcSEcCtD
Nabumetone—Pancreatitis—Epirubicin—thyroid cancer	0.000425	0.00212	CcSEcCtD
Nabumetone—Vomiting—Sorafenib—thyroid cancer	0.000424	0.00212	CcSEcCtD
Nabumetone—Hypokalaemia—Doxorubicin—thyroid cancer	0.000422	0.00211	CcSEcCtD
Nabumetone—Angina pectoris—Epirubicin—thyroid cancer	0.000422	0.00211	CcSEcCtD
Nabumetone—Rash—Sorafenib—thyroid cancer	0.00042	0.0021	CcSEcCtD
Nabumetone—Dermatitis—Sorafenib—thyroid cancer	0.00042	0.0021	CcSEcCtD
Nabumetone—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000418	0.00209	CcSEcCtD
Nabumetone—Headache—Sorafenib—thyroid cancer	0.000417	0.00209	CcSEcCtD
Nabumetone—Gastritis—Doxorubicin—thyroid cancer	0.00041	0.00205	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—PTGS2—thyroid cancer	0.000405	0.0105	CbGpPWpGaD
Nabumetone—Dysuria—Epirubicin—thyroid cancer	0.000405	0.00202	CcSEcCtD
Nabumetone—Dysphagia—Doxorubicin—thyroid cancer	0.000401	0.002	CcSEcCtD
Nabumetone—Asthma—Doxorubicin—thyroid cancer	0.000401	0.002	CcSEcCtD
Nabumetone—Nausea—Sorafenib—thyroid cancer	0.000396	0.00198	CcSEcCtD
Nabumetone—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000395	0.00198	CcSEcCtD
Nabumetone—Weight increased—Epirubicin—thyroid cancer	0.000394	0.00197	CcSEcCtD
Nabumetone—Pancreatitis—Doxorubicin—thyroid cancer	0.000393	0.00196	CcSEcCtD
Nabumetone—Weight decreased—Epirubicin—thyroid cancer	0.000392	0.00196	CcSEcCtD
Nabumetone—Hyperglycaemia—Epirubicin—thyroid cancer	0.000391	0.00195	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000391	0.0101	CbGpPWpGaD
Nabumetone—Angina pectoris—Doxorubicin—thyroid cancer	0.00039	0.00195	CcSEcCtD
Nabumetone—Pneumonia—Epirubicin—thyroid cancer	0.000388	0.00194	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000383	0.00191	CcSEcCtD
Nabumetone—Renal failure—Epirubicin—thyroid cancer	0.00038	0.0019	CcSEcCtD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000378	0.00976	CbGpPWpGaD
Nabumetone—Jaundice—Epirubicin—thyroid cancer	0.000376	0.00188	CcSEcCtD
Nabumetone—Stomatitis—Epirubicin—thyroid cancer	0.000376	0.00188	CcSEcCtD
Nabumetone—Dysuria—Doxorubicin—thyroid cancer	0.000375	0.00187	CcSEcCtD
Nabumetone—Haematuria—Epirubicin—thyroid cancer	0.000368	0.00184	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—CCND1—thyroid cancer	0.000366	0.00945	CbGpPWpGaD
Nabumetone—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000366	0.00183	CcSEcCtD
Nabumetone—Weight increased—Doxorubicin—thyroid cancer	0.000365	0.00182	CcSEcCtD
Nabumetone—Weight decreased—Doxorubicin—thyroid cancer	0.000363	0.00181	CcSEcCtD
Nabumetone—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000361	0.00181	CcSEcCtD
Nabumetone—Agranulocytosis—Epirubicin—thyroid cancer	0.00036	0.0018	CcSEcCtD
Nabumetone—Pneumonia—Doxorubicin—thyroid cancer	0.000359	0.0018	CcSEcCtD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000354	0.00915	CbGpPWpGaD
Nabumetone—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000354	0.00177	CcSEcCtD
Nabumetone—Renal failure—Doxorubicin—thyroid cancer	0.000351	0.00175	CcSEcCtD
Nabumetone—Haemoglobin—Epirubicin—thyroid cancer	0.000348	0.00174	CcSEcCtD
Nabumetone—Stomatitis—Doxorubicin—thyroid cancer	0.000348	0.00174	CcSEcCtD
Nabumetone—Jaundice—Doxorubicin—thyroid cancer	0.000348	0.00174	CcSEcCtD
Nabumetone—Haemorrhage—Epirubicin—thyroid cancer	0.000347	0.00173	CcSEcCtD
Nabumetone—Haematuria—Doxorubicin—thyroid cancer	0.000341	0.0017	CcSEcCtD
Nabumetone—Visual impairment—Epirubicin—thyroid cancer	0.000334	0.00167	CcSEcCtD
Nabumetone—Agranulocytosis—Doxorubicin—thyroid cancer	0.000333	0.00167	CcSEcCtD
Nabumetone—Erythema multiforme—Epirubicin—thyroid cancer	0.000328	0.00164	CcSEcCtD
Nabumetone—Tinnitus—Epirubicin—thyroid cancer	0.000323	0.00161	CcSEcCtD
Nabumetone—Haemoglobin—Doxorubicin—thyroid cancer	0.000322	0.00161	CcSEcCtD
Nabumetone—Haemorrhage—Doxorubicin—thyroid cancer	0.000321	0.0016	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000319	0.00822	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—NRAS—thyroid cancer	0.000315	0.00814	CbGpPWpGaD
Nabumetone—Chills—Epirubicin—thyroid cancer	0.000311	0.00155	CcSEcCtD
Nabumetone—Arrhythmia—Epirubicin—thyroid cancer	0.00031	0.00155	CcSEcCtD
Nabumetone—Visual impairment—Doxorubicin—thyroid cancer	0.000309	0.00154	CcSEcCtD
Nabumetone—Alopecia—Epirubicin—thyroid cancer	0.000306	0.00153	CcSEcCtD
Nabumetone—Erythema multiforme—Doxorubicin—thyroid cancer	0.000303	0.00152	CcSEcCtD
Nabumetone—Tinnitus—Doxorubicin—thyroid cancer	0.000299	0.00149	CcSEcCtD
Nabumetone—Flatulence—Epirubicin—thyroid cancer	0.000297	0.00149	CcSEcCtD
Nabumetone—Tension—Epirubicin—thyroid cancer	0.000296	0.00148	CcSEcCtD
Nabumetone—Nervousness—Epirubicin—thyroid cancer	0.000293	0.00146	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TP53—thyroid cancer	0.000293	0.00755	CbGpPWpGaD
Nabumetone—Chills—Doxorubicin—thyroid cancer	0.000288	0.00144	CcSEcCtD
Nabumetone—Arrhythmia—Doxorubicin—thyroid cancer	0.000287	0.00143	CcSEcCtD
Nabumetone—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000286	0.00739	CbGpPWpGaD
Nabumetone—Alopecia—Doxorubicin—thyroid cancer	0.000283	0.00142	CcSEcCtD
Nabumetone—Ill-defined disorder—Epirubicin—thyroid cancer	0.00028	0.0014	CcSEcCtD
Nabumetone—Anaemia—Epirubicin—thyroid cancer	0.000279	0.00139	CcSEcCtD
Nabumetone—Agitation—Epirubicin—thyroid cancer	0.000277	0.00139	CcSEcCtD
Nabumetone—Flatulence—Doxorubicin—thyroid cancer	0.000275	0.00137	CcSEcCtD
Nabumetone—Tension—Doxorubicin—thyroid cancer	0.000274	0.00137	CcSEcCtD
Nabumetone—Malaise—Epirubicin—thyroid cancer	0.000272	0.00136	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—KRAS—thyroid cancer	0.000271	0.00701	CbGpPWpGaD
Nabumetone—Nervousness—Doxorubicin—thyroid cancer	0.000271	0.00136	CcSEcCtD
Nabumetone—Vertigo—Epirubicin—thyroid cancer	0.000271	0.00135	CcSEcCtD
Nabumetone—Syncope—Epirubicin—thyroid cancer	0.000271	0.00135	CcSEcCtD
Nabumetone—Leukopenia—Epirubicin—thyroid cancer	0.00027	0.00135	CcSEcCtD
Nabumetone—Palpitations—Epirubicin—thyroid cancer	0.000267	0.00133	CcSEcCtD
Nabumetone—Loss of consciousness—Epirubicin—thyroid cancer	0.000265	0.00133	CcSEcCtD
Nabumetone—Cough—Epirubicin—thyroid cancer	0.000263	0.00132	CcSEcCtD
Nabumetone—Hypertension—Epirubicin—thyroid cancer	0.000261	0.0013	CcSEcCtD
Nabumetone—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000259	0.00129	CcSEcCtD
Nabumetone—Anaemia—Doxorubicin—thyroid cancer	0.000258	0.00129	CcSEcCtD
Nabumetone—Agitation—Doxorubicin—thyroid cancer	0.000257	0.00128	CcSEcCtD
Nabumetone—Anxiety—Epirubicin—thyroid cancer	0.000256	0.00128	CcSEcCtD
Nabumetone—Discomfort—Epirubicin—thyroid cancer	0.000254	0.00127	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000254	0.00654	CbGpPWpGaD
Nabumetone—Malaise—Doxorubicin—thyroid cancer	0.000252	0.00126	CcSEcCtD
Nabumetone—Dry mouth—Epirubicin—thyroid cancer	0.000251	0.00126	CcSEcCtD
Nabumetone—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000251	0.00648	CbGpPWpGaD
Nabumetone—Vertigo—Doxorubicin—thyroid cancer	0.000251	0.00125	CcSEcCtD
Nabumetone—Syncope—Doxorubicin—thyroid cancer	0.00025	0.00125	CcSEcCtD
Nabumetone—Leukopenia—Doxorubicin—thyroid cancer	0.00025	0.00125	CcSEcCtD
Nabumetone—Confusional state—Epirubicin—thyroid cancer	0.000248	0.00124	CcSEcCtD
Nabumetone—Palpitations—Doxorubicin—thyroid cancer	0.000247	0.00123	CcSEcCtD
Nabumetone—Anaphylactic shock—Epirubicin—thyroid cancer	0.000246	0.00123	CcSEcCtD
Nabumetone—Oedema—Epirubicin—thyroid cancer	0.000246	0.00123	CcSEcCtD
Nabumetone—Loss of consciousness—Doxorubicin—thyroid cancer	0.000245	0.00123	CcSEcCtD
Nabumetone—Cough—Doxorubicin—thyroid cancer	0.000244	0.00122	CcSEcCtD
Nabumetone—Shock—Epirubicin—thyroid cancer	0.000242	0.00121	CcSEcCtD
Nabumetone—Thrombocytopenia—Epirubicin—thyroid cancer	0.000241	0.0012	CcSEcCtD
Nabumetone—Hypertension—Doxorubicin—thyroid cancer	0.000241	0.0012	CcSEcCtD
Nabumetone—Hyperhidrosis—Epirubicin—thyroid cancer	0.000238	0.00119	CcSEcCtD
Nabumetone—Anxiety—Doxorubicin—thyroid cancer	0.000237	0.00118	CcSEcCtD
Nabumetone—Discomfort—Doxorubicin—thyroid cancer	0.000235	0.00117	CcSEcCtD
Nabumetone—Anorexia—Epirubicin—thyroid cancer	0.000235	0.00117	CcSEcCtD
Nabumetone—Dry mouth—Doxorubicin—thyroid cancer	0.000232	0.00116	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—HRAS—thyroid cancer	0.000231	0.00595	CbGpPWpGaD
Nabumetone—Confusional state—Doxorubicin—thyroid cancer	0.00023	0.00115	CcSEcCtD
Nabumetone—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000228	0.00114	CcSEcCtD
Nabumetone—Oedema—Doxorubicin—thyroid cancer	0.000228	0.00114	CcSEcCtD
Nabumetone—Shock—Doxorubicin—thyroid cancer	0.000224	0.00112	CcSEcCtD
Nabumetone—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000223	0.00111	CcSEcCtD
Nabumetone—Insomnia—Epirubicin—thyroid cancer	0.000223	0.00111	CcSEcCtD
Nabumetone—Paraesthesia—Epirubicin—thyroid cancer	0.000221	0.00111	CcSEcCtD
Nabumetone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00022	0.0011	CcSEcCtD
Nabumetone—Dyspnoea—Epirubicin—thyroid cancer	0.00022	0.0011	CcSEcCtD
Nabumetone—Somnolence—Epirubicin—thyroid cancer	0.000219	0.00109	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000218	0.00562	CbGpPWpGaD
Nabumetone—Anorexia—Doxorubicin—thyroid cancer	0.000217	0.00109	CcSEcCtD
Nabumetone—Dyspepsia—Epirubicin—thyroid cancer	0.000217	0.00108	CcSEcCtD
Nabumetone—Decreased appetite—Epirubicin—thyroid cancer	0.000214	0.00107	CcSEcCtD
Nabumetone—Fatigue—Epirubicin—thyroid cancer	0.000212	0.00106	CcSEcCtD
Nabumetone—Constipation—Epirubicin—thyroid cancer	0.000211	0.00105	CcSEcCtD
Nabumetone—Insomnia—Doxorubicin—thyroid cancer	0.000206	0.00103	CcSEcCtD
Nabumetone—Paraesthesia—Doxorubicin—thyroid cancer	0.000205	0.00102	CcSEcCtD
Nabumetone—Dyspnoea—Doxorubicin—thyroid cancer	0.000203	0.00102	CcSEcCtD
Nabumetone—Feeling abnormal—Epirubicin—thyroid cancer	0.000203	0.00101	CcSEcCtD
Nabumetone—Somnolence—Doxorubicin—thyroid cancer	0.000203	0.00101	CcSEcCtD
Nabumetone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000201	0.00101	CcSEcCtD
Nabumetone—Dyspepsia—Doxorubicin—thyroid cancer	0.000201	0.001	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.0002	0.00516	CbGpPWpGaD
Nabumetone—Decreased appetite—Doxorubicin—thyroid cancer	0.000198	0.00099	CcSEcCtD
Nabumetone—Fatigue—Doxorubicin—thyroid cancer	0.000196	0.000982	CcSEcCtD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000196	0.00507	CbGpPWpGaD
Nabumetone—Urticaria—Epirubicin—thyroid cancer	0.000196	0.000978	CcSEcCtD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000195	0.00504	CbGpPWpGaD
Nabumetone—Constipation—Doxorubicin—thyroid cancer	0.000195	0.000974	CcSEcCtD
Nabumetone—Abdominal pain—Epirubicin—thyroid cancer	0.000195	0.000973	CcSEcCtD
Nabumetone—Body temperature increased—Epirubicin—thyroid cancer	0.000195	0.000973	CcSEcCtD
Nabumetone—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000188	0.00486	CbGpPWpGaD
Nabumetone—Feeling abnormal—Doxorubicin—thyroid cancer	0.000188	0.000938	CcSEcCtD
Nabumetone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000186	0.000931	CcSEcCtD
Nabumetone—Hypersensitivity—Epirubicin—thyroid cancer	0.000181	0.000907	CcSEcCtD
Nabumetone—Urticaria—Doxorubicin—thyroid cancer	0.000181	0.000905	CcSEcCtD
Nabumetone—Body temperature increased—Doxorubicin—thyroid cancer	0.00018	0.0009	CcSEcCtD
Nabumetone—Abdominal pain—Doxorubicin—thyroid cancer	0.00018	0.0009	CcSEcCtD
Nabumetone—Asthenia—Epirubicin—thyroid cancer	0.000177	0.000883	CcSEcCtD
Nabumetone—Pruritus—Epirubicin—thyroid cancer	0.000174	0.000871	CcSEcCtD
Nabumetone—Diarrhoea—Epirubicin—thyroid cancer	0.000169	0.000842	CcSEcCtD
Nabumetone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000168	0.000839	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000166	0.00428	CbGpPWpGaD
Nabumetone—Asthenia—Doxorubicin—thyroid cancer	0.000163	0.000817	CcSEcCtD
Nabumetone—Dizziness—Epirubicin—thyroid cancer	0.000163	0.000814	CcSEcCtD
Nabumetone—Pruritus—Doxorubicin—thyroid cancer	0.000161	0.000806	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.00016	0.00412	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000159	0.00411	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000159	0.0041	CbGpPWpGaD
Nabumetone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000158	0.00408	CbGpPWpGaD
Nabumetone—Vomiting—Epirubicin—thyroid cancer	0.000157	0.000782	CcSEcCtD
Nabumetone—Diarrhoea—Doxorubicin—thyroid cancer	0.000156	0.000779	CcSEcCtD
Nabumetone—Rash—Epirubicin—thyroid cancer	0.000155	0.000776	CcSEcCtD
Nabumetone—Dermatitis—Epirubicin—thyroid cancer	0.000155	0.000775	CcSEcCtD
Nabumetone—Headache—Epirubicin—thyroid cancer	0.000154	0.000771	CcSEcCtD
Nabumetone—Dizziness—Doxorubicin—thyroid cancer	0.000151	0.000753	CcSEcCtD
Nabumetone—Nausea—Epirubicin—thyroid cancer	0.000146	0.000731	CcSEcCtD
Nabumetone—Vomiting—Doxorubicin—thyroid cancer	0.000145	0.000724	CcSEcCtD
Nabumetone—Rash—Doxorubicin—thyroid cancer	0.000144	0.000718	CcSEcCtD
Nabumetone—Dermatitis—Doxorubicin—thyroid cancer	0.000144	0.000717	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000143	0.00368	CbGpPWpGaD
Nabumetone—Headache—Doxorubicin—thyroid cancer	0.000143	0.000713	CcSEcCtD
Nabumetone—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000138	0.00357	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000137	0.00355	CbGpPWpGaD
Nabumetone—Nausea—Doxorubicin—thyroid cancer	0.000135	0.000676	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000121	0.00313	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000121	0.00311	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000119	0.00307	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000118	0.00303	CbGpPWpGaD
Nabumetone—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000113	0.00291	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TRIM24—thyroid cancer	0.000111	0.00288	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CHST14—thyroid cancer	0.000111	0.00285	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—MINPP1—thyroid cancer	0.00011	0.00283	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CHST14—thyroid cancer	0.000105	0.0027	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.000102	0.00264	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TRIM33—thyroid cancer	9.94e-05	0.00256	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	9.39e-05	0.00242	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—NDUFA13—thyroid cancer	9.34e-05	0.00241	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	9.07e-05	0.00234	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.99e-05	0.00232	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—HPGD—thyroid cancer	8.91e-05	0.0023	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	8.82e-05	0.00228	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CHST14—thyroid cancer	8.78e-05	0.00227	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—RXRA—thyroid cancer	8.46e-05	0.00218	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	8.08e-05	0.00209	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	7.5e-05	0.00193	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.23e-05	0.00187	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—HPGD—thyroid cancer	7.07e-05	0.00183	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	6.87e-05	0.00177	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TCF7L1—thyroid cancer	6.63e-05	0.00171	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—MINPP1—thyroid cancer	6.21e-05	0.0016	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	6.17e-05	0.00159	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	5.97e-05	0.00154	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	5.95e-05	0.00154	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.74e-05	0.00148	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—NDUFA13—thyroid cancer	5.28e-05	0.00136	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—TPR—thyroid cancer	5.12e-05	0.00132	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PRKAR1A—thyroid cancer	5.04e-05	0.0013	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CHST14—thyroid cancer	4.97e-05	0.00128	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TPR—thyroid cancer	4.85e-05	0.00125	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PRKAR1A—thyroid cancer	4.77e-05	0.00123	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	4.57e-05	0.00118	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.56e-05	0.00118	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MEN1—thyroid cancer	4.56e-05	0.00118	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—TPR—thyroid cancer	4.06e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	4.06e-05	0.00105	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—HPGD—thyroid cancer	4e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PRKAR1A—thyroid cancer	4e-05	0.00103	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SLC5A5—thyroid cancer	3.83e-05	0.000989	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CALCA—thyroid cancer	3.63e-05	0.000937	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.62e-05	0.000935	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.59e-05	0.000927	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.43e-05	0.000885	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CDK1—thyroid cancer	3.29e-05	0.000849	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.25e-05	0.000838	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—RXRA—thyroid cancer	3.22e-05	0.000831	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.13e-05	0.000808	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SLC5A5—thyroid cancer	3.04e-05	0.000785	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NRG1—thyroid cancer	2.64e-05	0.000681	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—RXRA—thyroid cancer	2.56e-05	0.00066	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.49e-05	0.000642	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TERT—thyroid cancer	2.37e-05	0.000612	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—TPR—thyroid cancer	2.3e-05	0.000593	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HIF1A—thyroid cancer	2.27e-05	0.000585	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.26e-05	0.000584	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.05e-05	0.000529	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PPARG—thyroid cancer	2.03e-05	0.000525	CbGpPWpGaD
Nabumetone—PTGS2—Disease—BRAF—thyroid cancer	1.88e-05	0.000484	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.72e-05	0.000444	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PPARG—thyroid cancer	1.61e-05	0.000416	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.61e-05	0.000416	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTGS2—thyroid cancer	1.6e-05	0.000413	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—RXRA—thyroid cancer	1.45e-05	0.000373	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.41e-05	0.000363	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—PTEN—thyroid cancer	1.39e-05	0.00036	CbGpPWpGaD
Nabumetone—PTGS2—Disease—PTEN—thyroid cancer	1.32e-05	0.000341	CbGpPWpGaD
Nabumetone—PTGS2—Disease—NRAS—thyroid cancer	1.18e-05	0.000304	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—PTEN—thyroid cancer	1.11e-05	0.000286	CbGpPWpGaD
Nabumetone—PTGS2—Disease—KRAS—thyroid cancer	1.02e-05	0.000262	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PPARG—thyroid cancer	9.13e-06	0.000236	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HRAS—thyroid cancer	8.63e-06	0.000223	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—AKT1—thyroid cancer	8.04e-06	0.000207	CbGpPWpGaD
Nabumetone—PTGS2—Disease—AKT1—thyroid cancer	7.62e-06	0.000197	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTGS2—thyroid cancer	7.18e-06	0.000185	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—AKT1—thyroid cancer	6.38e-06	0.000165	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—PTEN—thyroid cancer	6.26e-06	0.000162	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—AKT1—thyroid cancer	3.61e-06	9.32e-05	CbGpPWpGaD
